161 related articles for article (PubMed ID: 11061551)
61. Gene expression of neuronal nitric oxide synthase and adrenomedullin in human neuroblastoma using real-time PCR.
Dötsch J; Harmjanz A; Christiansen H; Hänze J; Lampert F; Rascher W
Int J Cancer; 2000 Oct; 88(2):172-5. PubMed ID: 11004664
[TBL] [Abstract][Full Text] [Related]
62. Lack of Thy1 (CD90) expression in neuroblastomas is correlated with impaired survival.
Fiegel HC; Kaifi JT; Quaas A; Varol E; Krickhahn A; Metzger R; Sauter G; Till H; Izbicki JR; Erttmann R; Kluth D
Pediatr Surg Int; 2008 Jan; 24(1):101-5. PubMed ID: 17952444
[TBL] [Abstract][Full Text] [Related]
63. A biology-driven approach identifies the hypoxia gene signature as a predictor of the outcome of neuroblastoma patients.
Fardin P; Barla A; Mosci S; Rosasco L; Verri A; Versteeg R; Caron HN; Molenaar JJ; Ora I; Eva A; Puppo M; Varesio L
Mol Cancer; 2010 Jul; 9():185. PubMed ID: 20624283
[TBL] [Abstract][Full Text] [Related]
64. Stage-independent expression and genetic analysis of tp73 in neuroblastoma.
Romani M; Scaruffi P; Casciano I; Mazzocco K; Lo Cunsolo C; Cavazzana A; Gambini C; Boni L; De Bernardi B; Tonini GP
Int J Cancer; 1999 Aug; 84(4):365-9. PubMed ID: 10404087
[TBL] [Abstract][Full Text] [Related]
65. [Somatostatin receptors in non-endocrine tumours].
Casini Raggi C; Pinzani P; Gelmini S; Tricarico C; Orlando C; Calabrò A; Renzi D; Cianchi F; Valanzano R; Distante V; Cortesini C; Tonelli F; Cataliotti L; Cameron Smith M; Messerini L; Bianchi S; Pazzagli M; Serio M; Maggi M
Minerva Endocrinol; 2001 Sep; 26(3):149-58. PubMed ID: 11753238
[TBL] [Abstract][Full Text] [Related]
66. Identification of
Shao F; Wang Z; Wang S
DNA Cell Biol; 2021 Feb; 40(2):332-347. PubMed ID: 33393844
[TBL] [Abstract][Full Text] [Related]
67. HsMAD2 mRNA expression may be a predictor of sensitivity to paclitaxel and survival in neuroblastoma.
Otake K; Uchida K; Tanaka K; Koike Y; Inoue M; Matsushita K; Ueeda M; Hashimoto K; Kitajima T; Komada Y; Kusunoki M
Pediatr Surg Int; 2011 Feb; 27(2):217-23. PubMed ID: 21046120
[TBL] [Abstract][Full Text] [Related]
68. Expression of the neuron-specific protein CHD5 is an independent marker of outcome in neuroblastoma.
Garcia I; Mayol G; Rodríguez E; Suñol M; Gershon TR; Ríos J; Cheung NK; Kieran MW; George RE; Perez-Atayde AR; Casala C; Galván P; de Torres C; Mora J; Lavarino C
Mol Cancer; 2010 Oct; 9():277. PubMed ID: 20950435
[TBL] [Abstract][Full Text] [Related]
69. Prognostic significance of EPHB6, EFNB2, and EFNB3 expressions in neuroblastoma.
Tang XX; Zhao H; Robinson ME; Cnaan A; London W; Cohn SL; Cheung NK; Brodeur GM; Evans AE; Ikegaki N
Med Pediatr Oncol; 2000 Dec; 35(6):656-8. PubMed ID: 11107140
[TBL] [Abstract][Full Text] [Related]
70. Clinical Significance of Tyrosine Hydroxylase mRNA Transcripts in Peripheral Blood at Diagnosis in Patients with Neuroblastoma.
Lee NH; Son MH; Choi YB; Yi E; Lee JW; Yoo KH; Sung KW; Koo HH
Cancer Res Treat; 2016 Oct; 48(4):1399-1407. PubMed ID: 27034145
[TBL] [Abstract][Full Text] [Related]
71. The presence of Y674/Y675 phosphorylated NTRK1 via TP53 repression of PTPN6 expression as a potential prognostic marker in neuroblastoma.
Youssef G; Gillett C; Rampling D; Chagtai T; Virasami A; Barton J; Edwards D; Sebire N; Anderson J; Montano X
Hum Pathol; 2019 Apr; 86():182-192. PubMed ID: 30594749
[TBL] [Abstract][Full Text] [Related]
72. Evaluation of CD44 prognostic value in neuroblastoma: comparison with the other prognostic factors.
Combaret V; Lasset C; Frappaz D; Bouvier R; Thiesse P; Rebillard AC; Philip T; Favrot MC
Eur J Cancer; 1995; 31A(4):545-9. PubMed ID: 7576964
[TBL] [Abstract][Full Text] [Related]
73. GALNT2 suppresses malignant phenotypes through IGF-1 receptor and predicts favorable prognosis in neuroblastoma.
Ho WL; Chou CH; Jeng YM; Lu MY; Yang YL; Jou ST; Lin DT; Chang HH; Lin KH; Hsu WM; Huang MC
Oncotarget; 2014 Dec; 5(23):12247-59. PubMed ID: 25362349
[TBL] [Abstract][Full Text] [Related]
74. [CD44 expression: a new prognostic factor in neuroblastoma].
Combaret V; Lasset C; Bouvier R; Frappaz D; Thiesse P; Rebillard AC; Philip T; Favrot MC
Bull Cancer; 1995 Jan; 82(2):131-6. PubMed ID: 10846530
[TBL] [Abstract][Full Text] [Related]
75. Cyclin D1, a novel molecular marker of minimal residual disease, in metastatic neuroblastoma.
Cheung IY; Feng Y; Vickers A; Gerald W; Cheung NK
J Mol Diagn; 2007 Apr; 9(2):237-41. PubMed ID: 17384216
[TBL] [Abstract][Full Text] [Related]
76. Identification of DDX39A as a Potential Biomarker for Unfavorable Neuroblastoma Using a Proteomic Approach.
Otake K; Uchida K; Ide S; Kobayashi Y; Kobayashi I; Kusunoki M
Pediatr Blood Cancer; 2016 Feb; 63(2):221-7. PubMed ID: 26469522
[TBL] [Abstract][Full Text] [Related]
77.
Yue ZX; Huang C; Gao C; Xing TY; Liu SG; Li XJ; Zhao Q; Wang XS; Zhao W; Jin M; Ma XL
Cancer Cell Int; 2017; 17():43. PubMed ID: 28367105
[No Abstract] [Full Text] [Related]
78. Construction of a Prognostic Nomogram Based on Autophagy-Related Genes for Children With Neuroblastoma.
Ye G; Wang Y
Evol Bioinform Online; 2022; 18():11769343221120960. PubMed ID: 36046056
[TBL] [Abstract][Full Text] [Related]
79. Logic Learning Machine creates explicit and stable rules stratifying neuroblastoma patients.
Cangelosi D; Blengio F; Versteeg R; Eggert A; Garaventa A; Gambini C; Conte M; Eva A; Muselli M; Varesio L
BMC Bioinformatics; 2013; 14 Suppl 7(Suppl 7):S12. PubMed ID: 23815266
[TBL] [Abstract][Full Text] [Related]
80. Expression of the periostin mRNA level in neuroblastoma.
Sasaki H; Sato Y; Kondo S; Fukai I; Kiriyama M; Yamakawa Y; Fuji Y
J Pediatr Surg; 2002 Sep; 37(9):1293-7. PubMed ID: 12194119
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
